event presence logo
Unraveling cMET and MET:

Transforming NSCLC Management CME/CNE/CPE

Hilton Chicago
Sunday, June 2, 2024 | 6:45 pm - 7:45 pm CT
Supported by an independent educational grant from AbbVie Inc.

overview

Join Drs Camidge and Dagogo-Jack in Chicago as they discuss the latest information on MET-altered NSCLC. In this lively symposium, our expert faculty will explore the role of ADCs in the management of NSCLC, with a focus on cMET targeted agents. They will also cover MET-related activity as it relates to NSCLC and new therapeutic agents on the horizon. You don’t want to miss this exciting opportunity to interact with the experts!


Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

faculty

MODERATOR

D. Ross Camidge, MD, PhD

Professor of Medicine/Oncology

Joyce Zeff Chair in Lung Cancer Research

Director of Thoracic Oncology

University of Colorado Cancer Center

Aurora, Colorado

PANELIST

Ibiayi Dagogo-Jack, MD

Assistant Professor of Medicine

Harvard Medical School

Thoracic Oncologist

Internal Medicine/Medical Oncology

Massachusetts General Hospital

Boston, Massachusetts

AGENDA

6:45 pm

Welcome and Introduction

D. Ross Camidge, MD, PhD

6:50 pm

Segment 1: Setting the Stage for ADCs in NSCLC

Ibiayi Dagogo-Jack, MD

7:10 pm

Segment 2: MET and cMET: Exploring New Therapies and Pathways in NSCLC

D. Ross Camidge, MD, PhD

7:35 pm

Conclusions and Q&A

7:45 pm

Adjourn

LOCATION

Hilton Chicago

720 S Michigan Ave, Chicago, Illinois, 60605

Room: Continental A

GOAL STATEMENT

The goal of this activity is for learners to be better able to recognize the clinical characteristics and impact of MET alterations in the care of patients with NSCLC.

TARGET AUDIENCE

This activity is intended for oncologists, pathologists, surgeons, pulmonologists, and other clinicians who treat patients with NSCLC.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

  • Defining characteristics of MET alterations in NSCLC
  • Evolving evidence surrounding therapeutic approaches for the treatment of MET-altered NSCLC

Have greater competence related to

  • Devising treatment algorithms for ongoing care for patients with MET-altered NSCLC

Demonstrate greater confidence in their ability to

  • Recognize the impact of dynamic targeted therapies on future NSCLC management

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

accreditation logo
medscape logo

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Awarded up to 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-169-L01-P).

© 2024 MedscapeLIVE! All Rights Reserved | Terms of Service | Privacy Policy